← Back to Clinical Trials
Recruiting NCT07292545

NCT07292545 Video-Based Proprioceptive Exercise Program in ALS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07292545
Status Recruiting
Phase
Sponsor Tarsus University
Condition Amyotrophic Lateral Sclerosis
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2025-07-14
Primary Completion 2026-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
video based exercise

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 20 participants in total. It began in 2025-07-14 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

In the project, it was aimed to evaluate the proprioceptive system in the disease, which is still mysterious and therefore has no curative treatment under current conditions, and to examine the effects of the video-based proprioceptive home exercise programme on trunk and limb control and daily life activity as well as trunk and limb control. The study was planned to include 20 patients with a definite diagnosis of ALS. Proprioceptive sensory examination will be performed again in these patients, who are currently being followed up with ALS diagnosis and whose physical examination including neurological examination has been performed in detail, and the "Revised Amyotrophic Lateral Sclerosis Functional Rating Scale" (R-ALSFRS) will be applied to the patients. Subsequently, the patients will be followed up by applying a video-based proprioceptive home exercise programme 3 days a week for 8 weeks. At the end of the 8th week, a detailed neurological examination including proprioceptive sensation will be performed and the R-ALSFRS scale will be applied. In addition, ALS quality of life scale will be applied to the patients before and after the home programme. The data obtained after the treatment programme will be analysed and interpreted.

Eligibility Criteria

Inclusion Criteria:Inclusion Criteria: * ALS patients aged 18-70 * Those with a definite ALS diagnosis according to the Gold Coast criteria * Those who can sit independently * Those who have no cognitive problems * Those who agree to participate in the study will be included in the study. Exclusion Criteria: * ALS patients with neurological, orthopedic or visual dysfunction mimicking ALS, * Those who cannot complete active joint movements in the upper and lower extremities, * ALS patients who do not agree to participate in the study will not be included in the study.

Contact & Investigator

Central Contact

Evrim GOZ, Assoc. Prof.

✉ fzt_evrim@hotmail.com

📞 03246000033

Frequently Asked Questions

Who can join the NCT07292545 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Amyotrophic Lateral Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07292545 currently recruiting?

Yes, NCT07292545 is actively recruiting participants. Contact the research team at fzt_evrim@hotmail.com for enrollment information.

Where is the NCT07292545 trial being conducted?

This trial is being conducted at Mersin, Turkey (Türkiye).

Who is sponsoring the NCT07292545 clinical trial?

NCT07292545 is sponsored by Tarsus University. The trial plans to enroll 20 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology